Flurazepam Stats & Data

Flurazepam is rapidly absorbed but acts as a prodrug to N-desalkylflurazepam, which has a very long elimination half-life (roughly 47–100 hours), so effects can accumulate across nights and significantly impair next-day cognition, coordination, and reaction time. Driving impairment and increased accident risk are documented with benzodiazepines in general, and risk rises sharply if alcohol is also used; avoid driving or operating machinery not only the night of dosing but also the next day if residual sedation is present. Older adults eliminate benzodiazepines more slowly and face higher risks of falls, confusion, and amnesia; use the lowest dose possible and avoid long-acting hypnotics in this group where alternatives exist. Combining flurazepam with opioids or alcohol greatly increases the risk of life‑threatening respiratory depression; if any opioids are in use, do not take flurazepam and ensure naloxone availability in the household. Avoid combining with other CNS depressants such as GHB/GBL, barbiturates, or sedating antihistamines; even cannabis can meaningfully increase psychomotor impairment. People with pre‑existing respiratory disorders (e.g., OSA, COPD) are more susceptible to hypoventilation at sedative doses; medical oversight is advised, and flurazepam is generally a poor choice in these settings. Physical dependence can develop within weeks; never stop abruptly after repeated use—coordinate a slow, individualized taper with a clinician to mitigate severe withdrawal and seizure risk. In breastfeeding, flurazepam is generally not preferred due to long-acting metabolites and a report of infant sedation during multi‑drug exposure; if used, infants should be monitored for excessive drowsiness and poor feeding. In overdose, supportive care is first-line; flumazenil is typically avoided outside select scenarios because it can precipitate seizures—particularly in benzodiazepine‑tolerant patients or mixed TCA overdoses. Due to widespread circulation of counterfeit ‘benzodiazepine’ tablets (sometimes containing potent nitazene opioids), avoid non‑pharmacy sources; if exposure is possible, use drug‑checking services where available and never mix with depressants. Space doses by at least 24–48 hours and avoid ‘booster’ redoses at night; apparent early wear‑off can reflect redistribution, while the active metabolite persists and will compound next-day effects.